Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 234 entries
Sorted by: Best Match Show Resources per page
Transcriptomic Analysis of Short/Branched-Chain Acyl-Coenzyme a Dehydrogenase Knocked Out bMECs Revealed Its Regulatory Effect on Lipid Metabolism.

Frontiers in veterinary science

Jiang P, Iqbal A, Wang M, Li X, Fang X, Yu H, Zhao Z.
PMID: 34557544
Front Vet Sci. 2021 Sep 07;8:744287. doi: 10.3389/fvets.2021.744287. eCollection 2021.

The acyl-CoA dehydrogenase family of enzymes includes short/branched-chain acyl-CoA dehydrogenase (

Cite
Jiang P, Iqbal A, Wang M, et al. Transcriptomic Analysis of Short/Branched-Chain Acyl-Coenzyme a Dehydrogenase Knocked Out bMECs Revealed Its Regulatory Effect on Lipid Metabolism. Front Vet Sci. 2021;8:744287doi: 10.3389/fvets.2021.744287.
Jiang, P., Iqbal, A., Wang, M., Li, X., Fang, X., Yu, H., & Zhao, Z. (2021). Transcriptomic Analysis of Short/Branched-Chain Acyl-Coenzyme a Dehydrogenase Knocked Out bMECs Revealed Its Regulatory Effect on Lipid Metabolism. Frontiers in veterinary science, 8744287. https://doi.org/10.3389/fvets.2021.744287
Jiang, Ping, et al. "Transcriptomic Analysis of Short/Branched-Chain Acyl-Coenzyme a Dehydrogenase Knocked Out bMECs Revealed Its Regulatory Effect on Lipid Metabolism." Frontiers in veterinary science vol. 8 (2021): 744287. doi: https://doi.org/10.3389/fvets.2021.744287
Jiang P, Iqbal A, Wang M, Li X, Fang X, Yu H, Zhao Z. Transcriptomic Analysis of Short/Branched-Chain Acyl-Coenzyme a Dehydrogenase Knocked Out bMECs Revealed Its Regulatory Effect on Lipid Metabolism. Front Vet Sci. 2021 Sep 07;8:744287. doi: 10.3389/fvets.2021.744287. eCollection 2021. PMID: 34557544; PMCID: PMC8453006.
Copy Download .nbib Format: NLM
Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.

Cell death & disease

Hu X, Fatima S, Chen M, Huang T, Chen YW, Gong R, Wong HLX, Yu R, Song L, Kwan HY, Bian Z.
PMID: 34741022
Cell Death Dis. 2021 Nov 05;12(11):1053. doi: 10.1038/s41419-021-04247-w.

Currently, no frontline treatment is effective for the late-stage colorectal cancer (CRC). Understanding the molecular differences in different stages of CRC can help us to identify the critical therapeutic targets for designing therapeutic strategy. Our data show that c-Myc...

Cite
Hu X, Fatima S, Chen M, et al. Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level. Cell Death Dis. 2021;12(11):1053doi: 10.1038/s41419-021-04247-w.
Hu, X., Fatima, S., Chen, M., Huang, T., Chen, Y. W., Gong, R., Wong, H. L. X., Yu, R., Song, L., Kwan, H. Y., & Bian, Z. (2021). Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level. Cell death & disease, 12(11), 1053. https://doi.org/10.1038/s41419-021-04247-w
Hu, Xianjing, et al. "Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level." Cell death & disease vol. 12,11 (2021): 1053. doi: https://doi.org/10.1038/s41419-021-04247-w
Hu X, Fatima S, Chen M, Huang T, Chen YW, Gong R, Wong HLX, Yu R, Song L, Kwan HY, Bian Z. Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level. Cell Death Dis. 2021 Nov 05;12(11):1053. doi: 10.1038/s41419-021-04247-w. PMID: 34741022; PMCID: PMC8571272.
Copy Download .nbib Format: NLM
Neonatal Screening for Congenital Metabolic and Endocrine Disorders—Results From Germany for the Years 2006–2018.

Deutsches Arzteblatt international

Lüders A, Blankenstein O, Brockow I, Ensenauer R, Lindner M, Schulze A, Nennstiel U.
PMID: 33439822
Dtsch Arztebl Int. 2021 Feb 19;118. doi: 10.3238/arztebl.m2021.0009. Epub 2021 Feb 19.

BACKGROUND: The purpose of neonatal screening is the early detection of congenital metabolic and endocrine disorders that, if untreated, could lead to fatal crises or other long-term adverse sequelae. In Germany, neonatal screening is legally regulated. Quality-assurance reports ("DGNS...

Cite
Lüders A, Blankenstein O, Brockow I, et al. Neonatal Screening for Congenital Metabolic and Endocrine Disorders—Results From Germany for the Years 2006–2018. Dtsch Arztebl Int. 2021;118doi: 10.3238/arztebl.m2021.0009.
Lüders, A., Blankenstein, O., Brockow, I., Ensenauer, R., Lindner, M., Schulze, A., & Nennstiel, U. (2021). Neonatal Screening for Congenital Metabolic and Endocrine Disorders—Results From Germany for the Years 2006–2018. Deutsches Arzteblatt international, 118. https://doi.org/10.3238/arztebl.m2021.0009
Lüders, Anja, et al. "Neonatal Screening for Congenital Metabolic and Endocrine Disorders—Results From Germany for the Years 2006–2018." Deutsches Arzteblatt international vol. 118 (2021). doi: https://doi.org/10.3238/arztebl.m2021.0009
Lüders A, Blankenstein O, Brockow I, Ensenauer R, Lindner M, Schulze A, Nennstiel U. Neonatal Screening for Congenital Metabolic and Endocrine Disorders—Results From Germany for the Years 2006–2018. Dtsch Arztebl Int. 2021 Feb 19;118. doi: 10.3238/arztebl.m2021.0009. Epub 2021 Feb 19. PMID: 33439822.
Copy Download .nbib Format: NLM
Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report.

Journal of medical case reports

Qatomah A, Bukhari M, Cupler E, Alardati H, Mawardi M.
PMID: 34924025
J Med Case Rep. 2021 Dec 19;15(1):627. doi: 10.1186/s13256-021-03138-0.

INTRODUCTION: Treatment of hepatitis C infection has evolved dramatically since 2011. Previous conventional therapy with interferon and ribavirin used to have a low sustained virological response rate of less than 40%. In the new direct-acting antiviral therapy era, a...

Cite
Qatomah A, Bukhari M, Cupler E, et al. Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report. J Med Case Rep. 2021;15(1):627doi: 10.1186/s13256-021-03138-0.
Qatomah, A., Bukhari, M., Cupler, E., Alardati, H., & Mawardi, M. (2021). Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report. Journal of medical case reports, 15(1), 627. https://doi.org/10.1186/s13256-021-03138-0
Qatomah, Abdulrahman, et al. "Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report." Journal of medical case reports vol. 15,1 (2021): 627. doi: https://doi.org/10.1186/s13256-021-03138-0
Qatomah A, Bukhari M, Cupler E, Alardati H, Mawardi M. Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report. J Med Case Rep. 2021 Dec 19;15(1):627. doi: 10.1186/s13256-021-03138-0. PMID: 34924025.
Copy Download .nbib Format: NLM
An Unusually High Excretion of Ethylmalonic Acid in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency.

Clinical chemistry

De Biase I, Yuzyuk T, Hernandez A, Basinger A.
PMID: 34470039
Clin Chem. 2021 Sep 01;67(9):1290-1292. doi: 10.1093/clinchem/hvab096.

No abstract available.

Cite
De Biase I, Yuzyuk T, Hernandez A, et al. An Unusually High Excretion of Ethylmalonic Acid in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency. Clin Chem. 2021;67(9):1290-1292doi: 10.1093/clinchem/hvab096.
De Biase, I., Yuzyuk, T., Hernandez, A., & Basinger, A. (2021). An Unusually High Excretion of Ethylmalonic Acid in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency. Clinical chemistry, 67(9), 1290-1292. https://doi.org/10.1093/clinchem/hvab096
De Biase, Irene, et al. "An Unusually High Excretion of Ethylmalonic Acid in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency." Clinical chemistry vol. 67,9 (2021): 1290-1292. doi: https://doi.org/10.1093/clinchem/hvab096
De Biase I, Yuzyuk T, Hernandez A, Basinger A. An Unusually High Excretion of Ethylmalonic Acid in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency. Clin Chem. 2021 Sep 01;67(9):1290-1292. doi: 10.1093/clinchem/hvab096. PMID: 34470039.
Copy Download .nbib Format: NLM
Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse.

Molecular genetics and metabolism reports

Diekman EF, van Weeghel M, Suárez-Fariñas M, Argmann C, Ranea-Robles P, Wanders RJA, Visser G, van der Made I, Creemers EE, Houten SM.
PMID: 33868931
Mol Genet Metab Rep. 2021 Mar 30;27:100749. doi: 10.1016/j.ymgmr.2021.100749. eCollection 2021 Jun.

Patients with a disorder of mitochondrial long-chain fatty acid β-oxidation (FAO) have reduced fasting tolerance and may present with hypoketotic hypoglycemia, hepatomegaly, (cardio)myopathy and rhabdomyolysis. Patients should avoid a catabolic state because it increases reliance on FAO as energy...

Cite
Diekman EF, van Weeghel M, Suárez-Fariñas M, et al. Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse. Mol Genet Metab Rep. 2021;27:100749doi: 10.1016/j.ymgmr.2021.100749.
Diekman, E. F., van Weeghel, M., Suárez-Fariñas, M., Argmann, C., Ranea-Robles, P., Wanders, R. J. A., Visser, G., van der Made, I., Creemers, E. E., & Houten, S. M. (2021). Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse. Molecular genetics and metabolism reports, 27100749. https://doi.org/10.1016/j.ymgmr.2021.100749
Diekman, Eugène F, et al. "Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse." Molecular genetics and metabolism reports vol. 27 (2021): 100749. doi: https://doi.org/10.1016/j.ymgmr.2021.100749
Diekman EF, van Weeghel M, Suárez-Fariñas M, Argmann C, Ranea-Robles P, Wanders RJA, Visser G, van der Made I, Creemers EE, Houten SM. Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse. Mol Genet Metab Rep. 2021 Mar 30;27:100749. doi: 10.1016/j.ymgmr.2021.100749. eCollection 2021 Jun. PMID: 33868931; PMCID: PMC8040332.
Copy Download .nbib Format: NLM
Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency.

Case reports in critical care

Dernoncourt A, Bouchereau J, Acquaviva-Bourdain C, Wicker C, De Lonlay P, Gourguechon C, Sevestre H, Merle PE, Maizel J, Brault C.
PMID: 31934457
Case Rep Crit Care. 2019 Dec 21;2019:1598213. doi: 10.1155/2019/1598213. eCollection 2019.

BACKGROUND: Multiple acyl-coA dehydrogenase deficiency (MADD) is a rare, inherited, autosomal-recessive disorder leading to the accumulation of acylcarnitine of all chain lengths. Acute decompensation with cardiac, respiratory or hepatic failure and metabolic abnormalities may be life-threatening.CASE PRESENTATION: A 29-year-old...

Cite
Dernoncourt A, Bouchereau J, Acquaviva-Bourdain C, et al. Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency. Case Rep Crit Care. 2019;2019:1598213doi: 10.1155/2019/1598213.
Dernoncourt, A., Bouchereau, J., Acquaviva-Bourdain, C., Wicker, C., De Lonlay, P., Gourguechon, C., Sevestre, H., Merle, P. E., Maizel, J., & Brault, C. (2019). Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency. Case reports in critical care, 20191598213. https://doi.org/10.1155/2019/1598213
Dernoncourt, A, et al. "Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency." Case reports in critical care vol. 2019 (2019): 1598213. doi: https://doi.org/10.1155/2019/1598213
Dernoncourt A, Bouchereau J, Acquaviva-Bourdain C, Wicker C, De Lonlay P, Gourguechon C, Sevestre H, Merle PE, Maizel J, Brault C. Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency. Case Rep Crit Care. 2019 Dec 21;2019:1598213. doi: 10.1155/2019/1598213. eCollection 2019. PMID: 31934457; PMCID: PMC6942752.
Copy Download .nbib Format: NLM
Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result.

Journal of community genetics

Atkins AE, Tarini BA, Phillips EK, Calhoun ARUL.
PMID: 30721391
J Community Genet. 2019 Oct;10(4):447-451. doi: 10.1007/s12687-019-00409-8. Epub 2019 Feb 05.

The Iowa Newborn Screening (NBS) Program began screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) in 2003. Untreated VLCAD can lead to liver failure, heart failure, and death. Current confirmatory testing recommendations by the American College of Medical Genetics...

Cite
Atkins AE, Tarini BA, Phillips EK, et al. Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result. J Community Genet. 2019;10(4):447-451doi: 10.1007/s12687-019-00409-8.
Atkins, A. E., Tarini, B. A., Phillips, E. K., & Calhoun, A. R. U. L. (2019). Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result. Journal of community genetics, 10(4), 447-451. https://doi.org/10.1007/s12687-019-00409-8
Atkins, Anne E, et al. "Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result." Journal of community genetics vol. 10,4 (2019): 447-451. doi: https://doi.org/10.1007/s12687-019-00409-8
Atkins AE, Tarini BA, Phillips EK, Calhoun ARUL. Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result. J Community Genet. 2019 Oct;10(4):447-451. doi: 10.1007/s12687-019-00409-8. Epub 2019 Feb 05. PMID: 30721391; PMCID: PMC6754489.
Copy Download .nbib Format: NLM
Healing of a Chronic Pressure Injury in a Patient Treated With Medical Cannabis for Pain and Sleep Improvement: A Case Report.

Wound management & prevention

Diaz PL, Katz TM, Langleben AC, Rabinovitch BS, Lewis EC.
PMID: 35030093
Wound Manag Prev. 2021 Oct;67(10):42-47.

BACKGROUND: A small body of evidence suggests medical cannabis may facilitate wound healing, but the exact mechanism of this effect is unclear.PURPOSE: This case report describes a patient with a pressure injury (PI) who received cannabis oil treatment for...

Cite
Diaz PL, Katz TM, Langleben AC, et al. Healing of a Chronic Pressure Injury in a Patient Treated With Medical Cannabis for Pain and Sleep Improvement: A Case Report. Wound Manag Prev. 2021;67(10):42-47
Diaz, P. L., Katz, T. M., Langleben, A. C., Rabinovitch, B. S., & Lewis, E. C. (2021). Healing of a Chronic Pressure Injury in a Patient Treated With Medical Cannabis for Pain and Sleep Improvement: A Case Report. Wound management & prevention, 67(10), 42-47.
Diaz, Patrick L, et al. "Healing of a Chronic Pressure Injury in a Patient Treated With Medical Cannabis for Pain and Sleep Improvement: A Case Report." Wound management & prevention vol. 67,10 (2021): 42-47.
Diaz PL, Katz TM, Langleben AC, Rabinovitch BS, Lewis EC. Healing of a Chronic Pressure Injury in a Patient Treated With Medical Cannabis for Pain and Sleep Improvement: A Case Report. Wound Manag Prev. 2021 Oct;67(10):42-47. PMID: 35030093.
Copy Download .nbib Format: NLM
Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation.

eLife

Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z.
PMID: 34939931
Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311.

Myocardial infarction (MI) is accompanied by severe energy deprivation and extensive epigenetic changes. However, how energy metabolism and chromatin modifications are interlinked during MI and heart repair has been poorly explored. Here, we examined the effect of different carbon...

Cite
Lei I, Tian S, Gao W, et al. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021;10doi: 10.7554/eLife.60311.
Lei, I., Tian, S., Gao, W., Liu, L., Guo, Y., Tang, P., Chen, E., & Wang, Z. (2021). Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. eLife, 10. https://doi.org/10.7554/eLife.60311
Lei, Ienglam, et al. "Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.60311
Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311. PMID: 34939931.
Copy Download .nbib Format: NLM
Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report.

JIMD reports

Wongkittichote P, Watson JR, Leonard JM, Toolan ER, Dickson PI, Grange DK.
PMID: 33204595
JIMD Rep. 2020 Sep 10;56(1):40-45. doi: 10.1002/jmd2.12165. eCollection 2020 Nov.

Long-chain fatty-acyl CoA dehydrogenase deficiency (LCHADD) is an inborn error of long chain fatty acid oxidation with various features including hypoketotic hypoglycemia, recurrent rhabdomyolysis, pigmentary retinopathy, peripheral neuropathy, cardiomyopathy, and arrhythmias. Various stresses trigger metabolic decompensation. Coronavirus disease 2019...

Cite
Wongkittichote P, Watson JR, Leonard JM, et al. Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report. JIMD Rep. 2020;56(1):40-45doi: 10.1002/jmd2.12165.
Wongkittichote, P., Watson, J. R., Leonard, J. M., Toolan, E. R., Dickson, P. I., & Grange, D. K. (2020). Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report. JIMD reports, 56(1), 40-45. https://doi.org/10.1002/jmd2.12165
Wongkittichote, Parith, et al. "Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report." JIMD reports vol. 56,1 (2020): 40-45. doi: https://doi.org/10.1002/jmd2.12165
Wongkittichote P, Watson JR, Leonard JM, Toolan ER, Dickson PI, Grange DK. Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report. JIMD Rep. 2020 Sep 10;56(1):40-45. doi: 10.1002/jmd2.12165. eCollection 2020 Nov. PMID: 33204595; PMCID: PMC7653242.
Copy Download .nbib Format: NLM
Essential oils can cause false-positive results of medium-chain acyl-CoA dehydrogenase deficiency.

Molecular genetics and metabolism reports

Mikami-Saito Y, Maekawa M, Wada Y, Kanno T, Kurihara A, Sato Y, Yamamoto T, Arai-Ichinoi N, Kure S.
PMID: 33204637
Mol Genet Metab Rep. 2020 Nov 05;25:100674. doi: 10.1016/j.ymgmr.2020.100674. eCollection 2020 Dec.

Newborn screening is a public health care program worldwide to prevent patients from critical illness or conditions. Tandem mass spectrometry allows multiplex, inexpensive, and rapid newborn screening. However, mass spectrometry used for newborn screening to date is not able...

Cite
Mikami-Saito Y, Maekawa M, Wada Y, et al. Essential oils can cause false-positive results of medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab Rep. 2020;25:100674doi: 10.1016/j.ymgmr.2020.100674.
Mikami-Saito, Y., Maekawa, M., Wada, Y., Kanno, T., Kurihara, A., Sato, Y., Yamamoto, T., Arai-Ichinoi, N., & Kure, S. (2020). Essential oils can cause false-positive results of medium-chain acyl-CoA dehydrogenase deficiency. Molecular genetics and metabolism reports, 25100674. https://doi.org/10.1016/j.ymgmr.2020.100674
Mikami-Saito, Yasuko, et al. "Essential oils can cause false-positive results of medium-chain acyl-CoA dehydrogenase deficiency." Molecular genetics and metabolism reports vol. 25 (2020): 100674. doi: https://doi.org/10.1016/j.ymgmr.2020.100674
Mikami-Saito Y, Maekawa M, Wada Y, Kanno T, Kurihara A, Sato Y, Yamamoto T, Arai-Ichinoi N, Kure S. Essential oils can cause false-positive results of medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab Rep. 2020 Nov 05;25:100674. doi: 10.1016/j.ymgmr.2020.100674. eCollection 2020 Dec. PMID: 33204637; PMCID: PMC7653163.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 234 entries